

Medicines Optimisation Advice Bulletin - October 2023

For the attention of primary and secondary care staff involved in patient care

Daridorexant for treating insomnia disorder

NICE are currently developing guidance on the use of [Daridorexant \(QUVIVIQ®\)](#) for treating insomnia disorder. The expected publication date is 18th October 2023.

Once this is published, it will progress through the Norfolk and Waveney ICB commissioning process. This will involve a formulary application to identify estimated patient numbers, position in treatment pathway and confirmation of prescribing responsibility.

As this will be a NICE Technology Appraisal, we will have 90 days from date of publication to commission and ensure availability of this treatment for prescribers and patients.

Therefore, there should be **no prescribing of Daridorexant in primary or secondary care until commissioning arrangements have been confirmed**. This will likely be early in the new year.

Once commissioned, it will be added to Netformulary and published in the TAG guidance. Prescribers will be notified via the usual communication channels.

Please email the medicines optimisation team with 'TAG' in the subject line if you have any further questions or comments - nwicb.medsqueries@nhs.net.

Many thanks for your support.

Sent on behalf of the Norfolk and Waveney Therapeutics Advisory Group